Abstract
THE growing cost of health care has heightened the pressure to decrease costs while maintaining or improving clinical outcome. One area of transplantation that is frequently referred to as “costly” is rejection. Immunosuppressive drug regimens may be differentiated primarily on the basis of whether or not polyclonal or monoclonal antibodies are used for induction in the early transplant therapy. Proponents of induction therapy have argued that the incidence of rejection is less and that overall costs are reduced when induction is utilized. However, no attempt has been previously reported to specifically analyze the cost (not charges) associated with rejection following liver transplantation. Consequently, we retrospectively examined episodes of acute rejection in liver transplant patients to determine the costs associated with the diagnosis, management, and complications of organ rejection.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
